Context: Bone metastases are a common complication in patients with advanced cancer but little is known regarding current practice patterns of palliative care providers when prescribing corticosteroids as adjuvant therapy for painful bone metastases. Objective: To identify current practice patterns among palliative care providers when prescribing corticosteroids for the treatment of painful bone metastases. Methods: A cross-sectional, online survey of the membership of the American Academy of Hospice and Palliative Medicine. Providers were asked to report how frequently they prescribed corticosteroids as adjuvant therapy in patients with painful bone metastases, and to specify the corticosteroid, dosage, treatment duration, and the gastroprotective strategy most frequently utilized. Results: Seven hundred sixty-five participants responded to the survey and 600 (78%) of respondents completed the survey. Ninety-eight percent of respondents completing the survey reported having prescribed corticosteroids as adjuvant pain therapy, and 66% ordered corticosteroids for the majority of their patients with painful bone metastases. Dexamethasone was the most widely prescribed corticosteroid. Eight milligrams divided twice daily was the most common dosage selected and once started, it was usually continued indefinitely. Conclusion: Corticosteroids are commonly prescribed as adjuvant therapy in the treatment of painful bone metastases in patients with limited life expectancy. Dexamethasone is the most commonly selected corticosteroid by American palliative care providers with variation existing among providers regarding dosing schedule, treatment duration, and gastroprotective strategies. Clinical trials comparing a total daily dose of four versus eight milligrams of dexamethasone would be clinically useful to inform evidence-based practice.
Introduction
Bone metastases are a common complication in patients with advanced cancer affecting over 330 000 Americans annually. 1 They occur in over 70% of patients with breast or prostate cancer and are the leading cause of cancer pain. [2] [3] [4] In addition, bone metastases are associated with reduced quality of life and a significant economic burden for both patients and society. [5] [6] [7] Corticosteroids have been utilized as an adjuvant therapy for the treatment of painful bone metastases for the past 3 decades, despite their uncertain efficacy. 8 Although the exact mechanism remains unclear, corticosteroids have been hypothesized to affect all 5 stages of nociceptive pain, including transduction, conduction, transmission, modulation, and pain perception. 9 Previous clinical trials investigating the use of corticosteroids for the treatment of cancer pain have demonstrated variable results. Recent clinical trials in the palliative care population by Mercadante et al, Paulsen et al, and Yennurajalingam and Bruera found improvements in important clinical outcomes including quality of life, fatigue, and patient satisfaction but did not demonstrate pain relief. [10] [11] [12] A meta-analysis by Haywood et al, combining 6 clinical trials with a total of 372 patients with cancer treated with corticosteroids, found a statistically significant improvement in pain scores at 1 week, with the corticosteroid group scoring 0.84 points lower than the control group on a 0 to 10 numeric pain scale (2.93 vs 3.77). 13 Only 1 of the 6 included trials focused specifically on bone metastases, and it consisted of only 20 patients following vertebroplasty.
14 A separate prospective study of 37 patients with prostate cancer having symptomatic bone metastases published in 1989 found pain relief from low-dose corticosteroids in approximately one-third of patients at 1 month, but it is unclear if the response is generalizable to other malignancies. 8 Despite limited data on their efficacy and toxicity, the use of corticosteroids is increasing among palliative care providers. 15 One study of palliative care outpatients found that dexamethasone was the single most commonly added medication during initial consultations with 40% of all patients prescribed a corticosteroid. 16 Little information is currently known regarding practice patterns of palliative care providers when prescribing corticosteroids for the treatment of painful bone metastases. The current studies demonstrated considerable variation in the specific corticosteroid, dosage, treatment duration, and gastroprotective strategy selected. 17, 18 The objectives of our investigation were to (1) determine how frequently palliative care providers prescribe corticosteroids for their patients with cancer having painful bone metastases; (2) identify which corticosteroid, dosage, frequency of administration, duration of treatment, and tapering strategy are most commonly selected; and (3) determine which gastroprotective strategy is most commonly utilized. The goal is to obtain the information needed to design a comparative effectiveness trial to delineate the risks and benefits of corticosteroids when prescribed for patients with painful bone metastases.
Methods

Study Design and Study Population
In this study, we used a cross-sectional survey design to assess current practice patterns of palliative care providers when caring for patients with painful bone metastases. An e-mail was sent to the membership of the American Academy of Hospice and Palliative Medicine (AAHPM) with information about the study and an invitation to participate in the self-administered, confidential, online survey. Physicians and nurse practitioners were eligible to participate in the study, and informed consent was obtained from all participants. This study was approved by the institutional review board of the University of Pittsburgh.
Questionnaire Design and Development
We developed an electronic questionnaire using questions adapted from previous surveys of corticosteroid practice patterns of Japanese and Swedish physicians. [19] [20] [21] The questionnaire consisted of a total of 21 items using a combination of multiple choice, Likert scale, and free text questions. Seven items assessed specific prescribing patterns of corticosteroids; 2 items examined gastroprotective strategies; 11 items assessed provider demographics, including age, sex, race, ethnicity, primary work location, weekly direct clinical care hours, provider credentials, geographic practice region, primary specialty training, and secondary board certification; and 1 item elicited any further comments. Participant instructions on each page of the questionnaire included instructions that the items referred to the use of corticosteroids for adjuvant pain control in patients with bone metastases and a prognosis of less than 6 months and not for the treatment of brain metastases or spinal cord compression. The survey underwent cognitive testing with 12 palliative care physicians and pilot testing with 8 palliative care physicians to help ensure content validity. 22 The final version of the survey took from 3 to 7 minutes to complete with an average time of 5 minutes.
Data Collection
We used Survey Monkey for data collection, and all anonymous information were then downloaded to a secure server. In December 2014, an invitation e-mail containing an electronic link to the study was sent from AAHPM to all active members. Potential participants were advised that for each completed survey a US$10 donation would be made to Toys for Tots, a national charitable organization for children. A reminder e-mail was sent 2 additional times to nonrespondents and data collection continued until March of 2015. Personal identifiers were not included in the survey, and upon questionnaire completion, all anonymous responses were downloaded to a secure server at the University of Pittsburgh.
Measurements
Dependent variables. We assessed the percentage of patients with painful bone metastases in which corticosteroids are prescribed, the corticosteroid most frequently prescribed, dosage, administration frequency, treatment duration, tapering strategy, and gastroprotective strategy selected.
Independent variables. We obtained respondent age, gender, race, ethnicity, primary work location (community-/homebased palliative care, hospice, palliative care inpatient consult service, and palliative care outpatient clinic), direct hospice care hours worked per week (<10, 10-20, 21-30, 31-40, and >40), geographic region of practice, current position (physician, fellow, Certified Registered Nurse Practitioner [CRPN] , and other), primary specialty training (internal medicine, family medicine, and other), secondary board certification (hospice and palliative medicine, oncology, geriatrics, and other), and the completion of hospice and palliative medicine fellowship.
Statistical Analyses
Study variables were summarized using standard descriptive statistics. The w 2 analyses were conducted to examine the relative associations between independent and dependent variables. For analyses with low expected cell frequencies, we also conducted Fisher exact tests (Monte Carlo estimation). Exact tests were almost identical to those from w 2 tests, and we report P values from the w 2 analyses. P values of < .05 were considered significant. All reported results are from analyses conducted using the statistical software Stata version 14.0 for Microsoft windows (Stata Corp, College Station, Texas).
Results
There were a total of 765 (20%) people who responded to this survey of a total of 3868 physicians and nurse practitioners on the AAHPM e-mail list. These respondents included 614 (92%) attending physicians, 24 (4%) nurse practitioners, 19 (3%) fellows, and 13 (2%) others. Of these, 600 (78%) completed all of the items pertaining to corticosteroid practice patterns. Table 1 displays the demographic characteristics of survey respondents. The mean age of survey respondents was 50 years, with a range of 27 to 82. Approximately 51% of the respondents were female, and the most common work locations were palliative care inpatient consult service (45.6%) and hospice (40.8%). The most frequent response for direct clinical hours worked per week was more than 40 hours (29.4%). Table 2 displays which corticosteroid was most often selected as an adjuvant therapy for the treatment of painful bone metastases-672 (94.8%) reported prescribing dexamethasone, 34 (4.8%) reported prescribing prednisone, and 3 (0.4%) reported prescribing prednisolone. Figure 2 displays the total daily dosage (milligrams) that respondents prescribed to patients as an adjuvant therapy for the treatment of painful bone metastases. Dosages for nondexamethasone corticosteroids were converted to the dexamethasone equivalent dose. 23 The mean average daily corticosteroid dosage reported was 8.1 mg with a median dose of 8.0 mg (range: 0.75-200 mg standard deviation [SD]: 10.01). The most commonly reported total daily prescribed dosages were 8 and 4 mg, with 46% and 32% of respondents selecting these dosages, respectively. Table 2 details the selected frequency of corticosteroid administration among respondents-652 (92%) respondents reported typically ordering the corticosteroid once (43%) or twice (49%) daily, whereas other respondents reported dividing the total dose 3 (3.2%), 4 (3.1%), or 5 or more (1.7%) times daily. Table 2 shows the selected duration of treatment among respondents. Three hundred fifty-nine (50.6%) respondents reported ''indefinitely'' as the duration for steroid treatment. The second most commonly reported duration for steroid treatment was 8 to 14 days, reported by 117 (16.5%) participants. Figure 1 . Provider reported utilization of corticosteroids for adjuvant pain control in patients with painful bone metastases. 
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Gastric Protection When Treating Painful Bone
Metastases With Corticosteroids Table 2 shows gastric protection treatment preferences among respondents. Six hundred sixteen respondents (88%) reported ordering a proton pump inhibitor treatment; 62 (9%) reported using a histamine-2 receptor antagonist for gastric protection when treating people for bone metastases. Table 3 shows the difference in gastric medication prescribing preferences in 3 different clinical situations-a patient started on corticosteroids alone, a patient prescribed both a corticosteroid and a nonsteroidal anti-inflammatory agent (NSAID), and a patient started on a corticosteroid with a history of gastrointestinal bleeding. Sixty-one percent of respondents typically prescribe gastroprotective agents when starting corticosteroids in their patients without other indications, whereas only 26% of respondents always prescribe them. The number of respondents always or usually prescribing gastroprotective agents increases to 82% for patients on concomitant NSAIDs and 94% in patients with a history of gastrointestinal bleeding. Table 4 displays the variation in corticosteroid usage in 4 dependent variables across the independent variable of primary work location. The w 2 analysis revealed a statistically significant difference in 3 of the 5 dependent variables-proportion of corticosteroid use, treatment duration, and tapering strategy. Gastroprotective strategy and corticosteroid dosing were not affected by work location.
Corticosteroid Usage Variation Across Primary Work Location
Discussion
This is the first survey of palliative care providers identifying practice patterns regarding the use of corticosteroids as an adjuvant therapy for painful bone metastases. The important findings of this study are as follows-(1) corticosteroids are frequently prescribed as an adjuvant therapy for painful bone metastases in patients with advanced disease; (2) relatively little variation exists regarding the corticosteroid selected but variation exists in the dosage, frequency of administration, duration of treatment, and tapering strategy selected; and (3) the majority of providers prescribe gastroprotection when ordering steroids in patients with a history of bleeding or concomitant NSAID use, but only Figure 2 . Total daily dosage of corticosteroid most frequently prescribed for adjuvant pain control in patients with painful bone metastases.
a quarter of respondents always prescribe gastroprotection in patients without other risk factors.
Over 98% of respondents have prescribed corticosteroids as an adjuvant therapy in the treatment of painful bone metastases, of which two-thirds utilize corticosteroids in the majority of their patients. As expected, respondents who categorized their primary work location as hospice had the highest corticosteroid use, followed by community-/homebased palliative care, palliative care inpatient consult services, and outpatient palliative care clinic providers. Despite some variation, it is notable that over 50% of respondents in all of the above settings prescribed steroids to the majority of their patients with painful bone metastases and a prognosis less than 6 months. These data confirm that steroids are widely utilized throughout the United States in both palliative care and hospice work settings. 
2 (6) 20 (7) 45 (15) 13 (23) Approximately 95% of palliative care respondents selected dexamethasone as their primary corticosteroid for the treatment of painful bone metastases. Internationally, variation exists with large national studies of palliative care providers in both Japan and Sweden selecting betamethasone as the corticosteroid of choice for symptom management of patients with advanced cancer, although neither study specifically addressed painful bone metastases. 19, 20 Little evidence exists to directly compare the side effect profiles of these 2 corticosteroids in the palliative care population, and this may represent another area of investigation for clinical trials.
Variation existed in the total daily dose of dexamethasone. After converting all corticosteroids into equivalent dosages of dexamethasone, the median dose was 8.0 mg with an SD of 10.01 and a range from 0.75 to 200 mg. Twelve percent selected a dose of 12 mg or greater and 36% selected a dose of 4 mg or less. The 2 most commonly reported dosages were 8 and 4 mg at 46% and 32%, respectively. This wide range is consistent with current expert guidelines that recommend initial dosing anywhere from a 1 to 24 mg daily total dosages of dexamethasone for painful bone metastases and up to 100 mg daily for suspected cord compression. 17, 18 These data suggest future clinical trials should compare 4 and 8 mg dosing strategies.
Variation was also found in the frequency of administration, duration of treatment, and tapering strategy selected. Forty-eight percent of respondents selected twice daily dosing compared to 44% selecting daily and 8% selecting other dosing schedules. Evidence regarding optimal frequency of administration is not clear given that corticosteroids work on multiple genomic and nongenomic factors, and no clinical trials have compared administration frequency in patients with cancer. One review article concluded that for low-dose maintenance therapy, twice daily corticosteroid dose fractions may allow for a lower total daily dose and a small reduction in side effects. 24 Dexamethasone has favorable pharmacokinetics and a longer half-life compared to other commonly prescribed corticosteroids in the United States that may be conducive to a once daily regimen, particularly in patients who may be at increased risk of nonadherence. 25 Treatment duration varied largely based on the respondent's primary work environment with over 73% of hospice providers selecting indefinite duration compared to only 25% of palliative care providers in the outpatient clinic setting. This is consistent with the shorter median life expectancy of hospice patients compared to the palliative care patients. Across all settings, about 40% of respondents typically tapered the medication off, including 34% of hospice providers and 55% of providers in the outpatient palliative care clinic environment. Of those providers typically using a defined tapering strategy, the most commonly utilized tapering strategies were a 1-to 13-day taper (49%), followed by a symptom response-based tapering approach (23%), and a 14-to 28-day taper (21%). A previous systematic review examining the use of corticosteroids in chronic diseases found insufficient evidence to recommend one tapering strategy over another. 26 Gastroprotective agents are used in the majority of patients prescribed corticosteroids with proton pump inhibitors being the preferred therapy. Sixty-one percent of respondents prescribe gastroprotective agents when starting corticosteroids in the majority of their patients without other indications, whereas only 26% of respondents always prescribe them. The vast majority of respondents typically prescribed gastroprotective agents in patients with risk factors such as concomitant NSAID (82%) use or a history of gastrointestinal bleeding (94%), with no significant variation across practice settings. A meta-analysis of 71 clinical trials found a 1.5 times increased relative risk of gastrointestinal bleeding in patients prescribed corticosteroids compared to controls but contained wide variation in corticosteroid dosing. 27 Another large study found the relative risk of gastrointestinal adverse events for patients on corticosteroids without NSAIDs to be only 1.1 times that of matched controls but that patients on both corticosteroids and NSAIDs had 15 times the risk of peptic ulcer disease. 28 Recent evidence suggests proton pump inhibitors may increase risk of pneumonia, fractures, and renal disease. [29] [30] [31] This has led to recent expert opinion that gastroprotective prophylaxis is not indicated for patients on corticosteroids alone without other major risk factors, and that patients without concomitant NSAID use are unlikely to benefit from gastroprotective prophylaxis. 32 This study has several limitations including an estimate overall response rate of between 15% and 25%. Of the 765 participants who actually opened the survey, 78% completed all items pertaining to corticosteroid practice patterns, which represents the largest survey of palliative care providers on corticosteroid practice patterns ever conducted, including approximately 10% of the estimated 6600 board-certified palliative care physicians in the United States. 33 No significant differences were identified between respondents and nonrespondents although suboptimal data existed for comparison. Second, our survey is generalizable only to palliative care providers in the United States with considerable variation when compared to surveys of physician practice patterns in Japan and Sweden. Third, our survey was also limited, in that, all outcomes were self-reported and not validated by other methods. The primary objective of the study was to obtain information that could lead to the development of comparative effectiveness trials.
In conclusion, American palliative care providers frequently prescribe corticosteroids as an adjuvant therapy for the treatment of painful bone metastases in patients with an expected prognosis less than 6 months. Dexamethasone was the corticosteroid of choice, with a dose of 8 mg divided twice daily continued indefinitely reported as the most commonly prescribed regimen, but variation existed among the total daily dosage, dose schedule, treatment duration, and gastroprotective strategy selected. Comparative effectiveness trials comparing a total daily dose of 4 mg versus 8 mg of dexamethasone may help provide clinicians evidence-based information to inform common prescribing patterns.
